Article
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
British journal of cancer - 1 Aug 2026
Kang Min Sil, Katuwal Nar Bahadur, Ghosh Mithun, Hong Sa Deok, Jeong Yeong Gyu, Park Seong Min, Kim Tae Hoen, Kim Seul-Gi, Lee Seung Ryeol, Moon Yong Wha
Abstract excerpt
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors are highly effective therapies for BRCA1/2-mutated tumors. However, most patients eventually develop acquired resistance. Here, we report that JPI-547, a second-generation PARP inhibitor targeting both PARP1/2 and tankyrase, demonstrates potent antitumor activity in olaparib-sensitive and resistant BRCA1/2 mutant models. METHODS: Olaparib-resistant (OR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.